/

Ricerca sul cancro

/

建立和表征三个抗阿法替尼的肺腺癌PC-9细胞系与增加剂量的阿法替尼开发

JoVE Journal
Ricerca sul cancro

È necessario avere un abbonamento a JoVE per visualizzare questo. Accedi o inizia la tua prova gratuita.

JoVE Journal Ricerca sul cancro

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Please note that all translations are automatically generated. Click here for the English version.

建立和表征三个抗阿法替尼的肺腺癌PC-9细胞系与增加剂量的阿法替尼开发

DOI:

10.3791/59473-v

•

09:38 min

•

June 26, 2019

•

Toshimitsu Yamaoka, Motoi Ohba, Yuki Matsunaga, Junji Tsurutani, Tohru Ohmori

¹Advanced Cancer Translational Research Institute,Showa University, ²Division of Breast Surgical Oncology, Department of Surgery,Showa University School of Medicine, ³Division of Allergology and Respiratory Medicine, Department of Medicine,Showa University School of Medicine

Capitoli

00:04Titolo
00:38Initial Afatinib PC-9 Cell Exposure Determination by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) Assay
01:46Continuous Afatinib Exposure
03:01PC-9 Cell Growth Curve Determination
03:46Epidermal Growth Factor Receptor (EGFR) Genomic DNA Alteration Evaluation
04:53Epidermal Growth Factor Receptor (EGFR) Protein Alteration Evaluation
07:39Results: Afatinib-resistant Cell Characterization
08:59Conclusion

Summary

Traduzione automatica

开发了一种从肺腺癌PC-9细胞中建立抗阿法替尼细胞系的方法,并对抗性细胞进行了特征描述。该耐药细胞可用于研究表皮生长因子受体酪氨酸激酶抑制剂抑制剂机制,适用于非小细胞肺癌患者。

Tags

Keywords: Afatinib Resistance Lung Adenocarcinoma PC-9 Cell Lines Acquired Resistance Stepwise Dose Escalation MTT Assay Cell Culture Subconfluency Dose-dependent Resistance

Article

Embed

AGGIUNGI ALLA PLAYLIST

Usage Statistics

Video correlati

建立双抗 EGFR-使用 tki 药物治疗和满足使用 tki 药物治疗在肺腺癌细胞体外与 2 步剂量升级程序

乳腺癌细胞系外周血单核细胞破的人前临床模型的建立

肺定植法在肺部组织循环肿瘤细胞可视化中的建立

合成肺腺癌细胞原位移植研究 pd-l1 表达

骨髓间充质干细胞在浆组织中的分离及与癌细胞联合培养研究其相互作用

建立胃癌患者衍生异种移植模型和原细胞系

肺癌细胞系中癌症干细胞的放射敏感性

小肠神经内分泌肿瘤类球体的建立与特征

患者衍生胰腺腺腺腺腺癌有机体模型的分离和特征

固体肿瘤细胞系侧面人口分析

Read Article